Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease
Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons, leading to the motor dysfunctions of patients. Although the etiology of PD is still unclear, the death of dopaminergic neurons during PD progress was revealed to be associated with the abnormal aggregation of α-synuclein, the elevation of oxidative stress, the dysfunction of mitochondrial functions, and the increase of neuroinflammation. However, current anti-PD therapies could only produce symptom-relieving effects, because they could not provide neuroprotective effects, stop or delay the degeneration of dopaminergic neurons. Marine-derived natural compounds, with their novel chemical structures and unique biological activities, may provide anti-PD neuroprotective effects. In this study, we have summarized anti-PD marine-derived natural products which have shown pharmacological activities by acting on various PD targets, such as α-synuclein, monoamine oxidase B, and reactive oxygen species. Moreover, marine-derived natural compounds currently evaluated in the clinical trials for the treatment of PD are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Marine drugs - 17(2019), 4 vom: 11. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Chunhui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-synuclein |
|---|
| Anmerkungen: |
Date Completed 03.09.2019 Date Revised 25.02.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/md17040221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295999268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295999268 | ||
| 003 | DE-627 | ||
| 005 | 20231225084901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/md17040221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0986.xml |
| 035 | |a (DE-627)NLM295999268 | ||
| 035 | |a (NLM)30978965 | ||
| 035 | |a (PII)E221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Chunhui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Marine-Derived Natural Compounds for the Treatment of Parkinson's Disease |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2019 | ||
| 500 | |a Date Revised 25.02.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons, leading to the motor dysfunctions of patients. Although the etiology of PD is still unclear, the death of dopaminergic neurons during PD progress was revealed to be associated with the abnormal aggregation of α-synuclein, the elevation of oxidative stress, the dysfunction of mitochondrial functions, and the increase of neuroinflammation. However, current anti-PD therapies could only produce symptom-relieving effects, because they could not provide neuroprotective effects, stop or delay the degeneration of dopaminergic neurons. Marine-derived natural compounds, with their novel chemical structures and unique biological activities, may provide anti-PD neuroprotective effects. In this study, we have summarized anti-PD marine-derived natural products which have shown pharmacological activities by acting on various PD targets, such as α-synuclein, monoamine oxidase B, and reactive oxygen species. Moreover, marine-derived natural compounds currently evaluated in the clinical trials for the treatment of PD are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a marine-derived natural compounds | |
| 650 | 4 | |a neuroprotective | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a α-synuclein | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 700 | 1 | |a Zhang, Zaijun |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Marine drugs |d 2007 |g 17(2019), 4 vom: 11. Apr. |w (DE-627)NLM179368389 |x 1660-3397 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2019 |g number:4 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/md17040221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2019 |e 4 |b 11 |c 04 | ||